23 Feb Accelerated Biosciences
Yuta Lee, CEO
April 13 | 1:30pm | Dark Horse Consulting Ballroom
Accelerated Biosciences discovered and has freedom-to-operate to the Human Trophoblast Stem Cell (hTSCs) platform for allogeneic therapies and bioproduction. The biggest challenge in regenerative medicine today is the availability of a clean and well-documented starting cell source. We can differentiate hTSCs into NK, neuronal, pancreatic, hepatic, and kidney cells as well as iPSCs. The iPSC RUO cells are available now. The hTSC GMP will be available in Q2 of 2023 for partnering and licensing opportunities.